PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to
be further improved, and the focus of improvement lies in "replacing cisplatin with
high-efficiency and low-toxicity treatment regimen". Considering the synergistic effect among
radiotherapy, immunotherapy and anti-angiogenesis therapy, we chose PD-1 inhibitor combined
with bevacizumab to replace cisplatin chemotherapy.